Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (Nasdaq: AUTL) announced the appointment of Ryan Richardson to its Board of Directors effective Dec 1, 2025.
Mr. Richardson brings more than 20 years of strategy and corporate development experience, including service as Chief Strategy Officer and management board member at BioNTech from Sept 2018 to Sept 2025. The company said his background in corporate development, capital markets, IPOs, financings and M&A will support Autolus' transition as a commercial-stage company and advance commercial launch and expansion efforts for obe-cel.
His prior roles include Executive Director at J.P. Morgan Global Healthcare Investment Banking (2011–2018) and chairmanship at Instadeep following BioNTech's 2023 acquisition.
Autolus Therapeutics (Nasdaq: AUTL) announced that NICE published draft guidance recommending AUCATZYL® (obecabtagene autoleucel) as a treatment option for adult patients aged ≥26 years with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (r/r B‑ALL).
AUCATZYL will be available through routine commissioning by the NHS in England and Wales and Autolus intends to launch imminently while pursuing Scottish access. The MHRA granted conditional marketing authorisation in April 2025, based on the FELIX study published in the New England Journal of Medicine in November 2024.
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Autolus Therapeutics (Nasdaq: AUTL) reported Q3 2025 results and operational updates on Nov 12, 2025. Key commercial metrics: Q3 net product revenue $21.1M, deferred revenue $7.6M, and 60 U.S. treatment centers activated as of Nov 12, 2025. Cash and marketable securities totaled $367.4M at Sept 30, 2025.
Clinical highlights include rmAT designation for obe-cel in pediatric r/r B-ALL, CARLYSLE Phase 1 data in severe refractory SLE showing DORIS remission in 83% (5/6) and CRR in 50% (3/6), and first patient dosed in a progressive MS Phase 1 trial. Management additions announced to support commercialization and manufacturing.
Autolus (Nasdaq: AUTL) announced five abstracts for presentation at the ASH Annual Meeting (Dec 6-9, 2025) detailing clinical updates for obe-cel (obecabtagene autoleucel) across autoimmune and hematologic indications.
Key points: Phase I CARLYSLE data in severe refractory SLE show pronounced CAR T expansion, deep B-cell depletion and clinical benefit; pediatric CATULUS trial reports ORR 95% and ~90% ongoing remissions at cutoff; drug-product phenotypes (higher Tcm) correlated with improved OS; Month 3 CAR T persistence predicts longer EFS/OS; commercially available reagents can track obe-cel but CD19-based reagents are unsuitable.
Autolus Therapeutics (Nasdaq: AUTL) will release its third quarter 2025 financial results and operational highlights before U.S. market open on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30 AM EST / 1:30 PM GMT to discuss results and provide a business update. Participants must pre-register to receive dial-in numbers and a personal PIN required for access. A simultaneous audio webcast and a replay will be available from the events section of Autolus’ investor website.
Autolus Therapeutics (NASDAQ: AUTL)/b) presented follow-up data from the Phase 1 CARLYSLE study of obe-cel in severe refractory systemic lupus erythematosus (srSLE) on Oct 27, 2025. As of Aug 21, 2025, six patients received the target dose of (±20%) with median follow-up of 8.9 months (range 6.0–13.8).
Key findings: no DLTs, no ICANS, no Grade ≥2 CRS; remission by DORIS in 83.3% (5/6); complete renal response in 50% (3/6); all patients tapered steroids to ≤5 mg/day; deep B-cell depletion followed by naïve B-cell reconstitution. Company expects to dose first Phase 2 LN patient before year-end 2025 and reports alignment with the FDA on trial design.
Autolus Therapeutics (Nasdaq: AUTL) announced dosing of the first patient in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis (PMS) on Oct 20, 2025. The trial, led at University College London Hospitals, will enroll up to 18 adults with refractory progressive MS to evaluate safety, tolerability and collect preliminary efficacy and biological-effect data using change-from-baseline standard measures. Autolus highlights obe-cel’s fast-off rate CAR design and notes the therapy has been studied in more than 400 patients to date and is approved in certain regions for adult relapsed/refractory B-ALL.
This dosing marks an early clinical milestone as the company explores a one-time CAR T approach for an unmet need in PMS.
Autolus Therapeutics (Nasdaq: AUTL) announced inducement stock option awards under its 2025 Inducement Plan on October 15, 2025.
The Compensation Committee granted options to purchase an aggregate of 1,093,300 shares to 65 employees. Options carry an exercise price of $1.49, equal to the closing price on October 7, 2025, have a 10-year term, and vest over four years (25% at one year, then 36 equal monthly installments), subject to continued service. Grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
Autolus Therapeutics (Nasdaq: AUTL) has announced it will present updated clinical data from its CARLYSLE study at the upcoming American College of Rheumatology (ACR) Convergence 2025, scheduled for October 24-29 in Chicago.
The presentation will focus on obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-cell therapy, in treating patients with severe refractory systemic lupus erythematosus (srSLE). Initial findings demonstrate a favorable safety profile with no dose limiting toxicities, no ICANS, and no Grade ≥2 cytokine release syndrome. The study showed SLEDAI-2K score improvements and clinical benefits across all patients, with three patients achieving complete renal response.